Tag Archives: Gilenia

Merck KGaA MS Drug on the Fast Track

Merck KGaA received word July 25 that its application for the multiple sclerosis treatment Cladribine had received priority review status by FDA, decreasing the evaluation period from 10 months to six months, and closing the gap between Merck and the competition. ‚ÄúThis is a critical milestone on the path to potential approval for short-course therapy […]
Posted in Strategy | Also tagged , , , , , , , | Leave a comment
  • Categories

  • Meta